Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin – A real-world data and retrospective cost analysis

Background: The treatment of acute bacterial skin and skin structure infections (ABSSSI) usually involves intravenous (i.v.) antibiotics requiring hospitalisation and increasing hospital costs. Since 2014, dalbavancin is approved for ABSSSIs treatment. However, evidence of its health economic impact...

Descripció completa

Dades bibliogràfiques

Autors principals:	Christoph T. Baltin, Carolin Wulf, Robert Rongisch, Clara Lehmann, Sebastian Wingen-Heimann, Nicole Eisenmenger, Jennifer Bonn, Mario Fabri, Esther von Stebut, Oliver A. Cornely, Florian Kron
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-06-01
Col·lecció:	Journal of Infection and Public Health
Matèries:	Acute bacterial skin and skin structure infection Antibiotics Cost saving Dalbavancin Health economics
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1876034123001363
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!